

In the Claims:

Please substitute the following claims:

---

121. (Amended) A method of genotyping comprising determining the identity of a nucleotide at a PCTA-1-related biallelic marker, or the complement of said nucleotide, in a biological sample.

---

141. (Thrice Amended) The method according to claim 132, wherein said control population is a random population.

---

150. (Amended) A method of determining whether an individual is at risk of developing prostate cancer, comprising:

- a) genotyping at least one PCTA-1-related biallelic marker according to the method of claim 123; and
  - b) correlating the result of step a) with one or more biallelic marker that is associated with a risk of developing prostate cancer.
- 

151. (Thrice Amended) The method according to claim 121, wherein said PCTA-1-related biallelic marker is selected from the group consisting of biallelic markers of SEQ ID No:1 located at positions 278, 402, 472, 2955, 12167, 12536, 17593, 17606, 22079, 28964, 29003, 31077, 31766, 34791, 45751, 49847, 49855, 49886, 49900, 49906, 49921, 49939, 50256, 54955, 64239, 65436, 65496, 66967, 66987, 67092, 67129, 67229, 67433, 67723, 67834, 67955, 68213, 68263, 68375, 68477, 68525, 68594, 68610, 70566, 70728, 80038, 80118, 80170, 80183, 80435, 82090, 82165, 82169, 82218, 82234, 82268, 82393, 83587, 83643, 83644, 83808, 83881, 83884, 83909, 83937, 83947, 83982, 83988, 84047, 84092, 84145, 85202, 86259, 86323, 87713, 87735, 87787, 87806, 87860, 87902, 87980, 88012, 88215, 88283, 88297, 88442, 88471, 88480, 89394, 89464, 89471, 89658, 92760, 93023, 93055, 93247, 93319, 93323, 93388, 93393, 93418, 93515, 93726, 93903, 94170, 94218, 94269, 94290, 94422, 94432, 94720, 94989, 95261, 95340, 95497, 95770, 95819, 96145, 96181, 96350, 96951, 97144, 97276, 102267, 105937 and any complement of said biallelic marker.

---

152. (Fourth Amendment) The method according to claim 150, wherein said PCTA-1-related biallelic marker is at least one PCTA-1-related biallelic marker located at position 402, 67092, 68525, 82234, or 82393 of SEQ ID NO. 1, and any complement of said biallelic marker.

167. (Twice Amended) The method according to claim 131, wherein said PCTA-1-related biallelic marker is selected from the group consisting of biallelic markers of SEQ ID No:1 located at positions 278, 402, 472, 2955, 12167, 12536, 17593, 17606, 22079, 28964, 29003, 31077, 31766, 34791, 45751, 49847, 49855, 49886, 49900, 49906, 49921, 49939, 50256, 54955, 64239, 65436, 65496, 66967, 66987, 67092, 67129, 67229, 67433, 67723, 67834, 67955, 68213, 68263, 68375, 68477, 68525, 68594, 68610, 70566, 70728, 80038, 80118, 80170, 80183, 80435, 82090, 82165, 82169, 82218, 82234, 82268, 82393, 83587, 83643, 83644, 83808, 83881, 83884, 83909, 83937, 83947, 83982, 83988, 84047, 84092, 84145, 85202, 86259, 86323, 87713, 87735, 87787, 87806, 87860, 87902, 87980, 88012, 88215, 88283, 88297, 88442, 88471, 88480, 89394, 89464, 89471, 89658, 92760, 93023, 93055, 93247, 93319, 93323, 93388, 93393, 93418, 93515, 93726, 93903, 94170, 94218, 94269, 94290, 94422, 94432, 94720, 94989, 95261, 95340, 95497, 95770, 95819, 96145, 96181, 96350, 96951, 97144, 97276, 102267, 105937 and any complement of said biallelic marker.

168. (Twice Amended) The method according to claim 132, wherein said PCTA-1-related biallelic marker is selected from the group consisting of biallelic markers of SEQ ID No:1 located at positions 278, 402, 472, 2955, 12167, 12536, 17593, 17606, 22079, 28964, 29003, 31077, 31766, 34791, 45751, 49847, 49855, 49886, 49900, 49906, 49921, 49939, 50256, 54955, 64239, 65436, 65496, 66967, 66987, 67092, 67129, 67229, 67433, 67723, 67834, 67955, 68213, 68263, 68375, 68477, 68525, 68594, 68610, 70566, 70728, 80038, 80118, 80170, 80183, 80435, 82090, 82165, 82169, 82218, 82234, 82268, 82393, 83587, 83643, 83644, 83808, 83881, 83884, 83909, 83937, 83947, 83982, 83988, 84047, 84092, 84145, 85202, 86259, 86323, 87713, 87735, 87787, 87806, 87860, 87902, 87980, 88012, 88215, 88283, 88297, 88442, 88471, 88480, 89394, 89464, 89471, 89658, 92760, 93023, 93055, 93247, 93319, 93323, 93388, 93393, 93418, 93515, 93726, 93903, 94170, 94218, 94269, 94290, 94422, 94432, 94720, 94989, 95261, 95340, 95497, 95770, 95819,

96145, 96181, 96350, 96951, 97144, 97276, 102267, 105937 and any complement of said biallelic marker.

169. (Twice Amended) The method according to claim 133, wherein said PCTA-1-related biallelic marker is selected from the group consisting of biallelic markers of SEQ ID No:1 located at positions 278, 402, 472, 2955, 12167, 12536, 17593, 17606, 22079, 28964, 29003, 31077, 31766, 34791, 45751, 49847, 49855, 49886, 49900, 49906, 49921, 49939, 50256, 54955, 64239, 65436, 65496, 66967, 66987, 67092, 67129, 67229, 67433, 67723, 67834, 67955, 68213, 68263, 68375, 68477, 68525, 68594, 68610, 70566, 70728, 80038, 80118, 80170, 80183, 80435, 82090, 82165, 82169, 82218, 82234, 82268, 82393, 83587, 83643, 83644, 83808, 83881, 83884, 83909, 83937, 83947, 83982, 83988, 84047, 84092, 84145, 85202, 86259, 86323, 87713, 87735, 87787, 87806, 87860, 87902, 87980, 88012, 88215, 88283, 88297, 88442, 88471, 88480, 89394, 89464, 89471, 89658, 92760, 93023, 93055, 93247, 93319, 93323, 93388, 93393, 93418, 93515, 93726, 93903, 94170, 94218, 94269, 94290, 94422, 94432, 94720, 94989, 95261, 95340, 95497, 95770, 95819, 96145, 96181, 96350, 96951, 97144, 97276, 102267, 105937, and any complement of said biallelic marker.

170. (Twice Amended) The method according to claim 135, wherein said PCTA-1-related biallelic marker is selected from the group consisting of biallelic markers of SEQ ID No:1 located at positions 278, 402, 472, 2955, 12167, 12536, 17593, 17606, 22079, 28964, 29003, 31077, 31766, 34791, 45751, 49847, 49855, 49886, 49900, 49906, 49921, 49939, 50256, 54955, 64239, 65436, 65496, 66967, 66987, 67092, 67129, 67229, 67433, 67723, 67834, 67955, 68213, 68263, 68375, 68477, 68525, 68594, 68610, 70566, 70728, 80038, 80118, 80170, 80183, 80435, 82090, 82165, 82169, 82218, 82234, 82268, 82393, 83587, 83643, 83644, 83808, 83881, 83884, 83909, 83937, 83947, 83982, 83988, 84047, 84092, 84145, 85202, 86259, 86323, 87713, 87735, 87787, 87806, 87860, 87902, 87980, 88012, 88215, 88283, 88297, 88442, 88471, 88480, 89394, 89464, 89471, 89658, 92760, 93023, 93055, 93247, 93319, 93323, 93388, 93393, 93418, 93515, 93726, 93903, 94170, 94218, 94269, 94290, 94422, 94432, 94720, 94989, 95261, 95340, 95497, 95770, 95819, 96145, 96181, 96350, 96951, 97144, 97276, 102267, 105937 and any complement of said biallelic marker.

171. (Twice Amended) The method according to claim 150, wherein said PCTA-1-related biallelic marker is selected from the group consisting of biallelic markers of SEQ ID No:1 located at positions 278, 402, 472, 2955, 12167, 12536, 17593, 17606, 22079, 28964, 29003, 31077, 31766, 34791, 45751, 49847, 49855, 49886, 49900, 49906, 49921, 49939, 50256, 54955, 64239, 65436, 65496, 66967, 66987, 67092, 67129, 67229, 67433, 67723, 67834, 67955, 68213, 68263, 68375, 68477, 68525, 68594, 68610, 70566, 70728, 80038, 80118, 80170, 80183, 80435, 82090, 82165, 82169, 82218, 82234, 82268, 82393, 83587, 83643, 83644, 83808, 83881, 83884, 83909, 83937, 83947, 83982, 83988, 84047, 84092, 84145, 85202, 86259, 86323, 87713, 87735, 87787, 87806, 87860, 87902, 87980, 88012, 88215, 88283, 88297, 88442, 88471, 88480, 89394, 89464, 89471, 89658, 92760, 93023, 93055, 93247, 93319, 93323, 93388, 93393, 93418, 93515, 93726, 93903, 94170, 94218, 94269, 94290, 94422, 94432, 94720, 94989, 95261, 95340, 95497, 95770, 95819, 96145, 96181, 96350, 96951, 97144, 97276, 102267, 105937 and any complement of said biallelic marker.

---

177. (Twice Amended) The method according to claim 133, wherein said PCTA-1-related biallelic marker is at least one PCTA-1-related biallelic marker located at position 402, 67092, 68525, 82234, or 82393 of SEQ ID NO. 1, and any complement of said biallelic marker.

---

178. (Amended) The method according to claim 177, wherein said PCTA-1-related biallelic marker is a combination of more than one PCTA-1-related biallelic marker or any complement of said biallelic marker.

---